pharmaphorum March 24, 2025
Novo Nordisk has moved to shore up its obesity pipeline in the face of less-than-stellar data with one of its late-stage candidates, paying $200 million upfront to buy rights to a drug from China’s United Biotechnology.
The deal – which could be worth up to $2 billion if all objectives are met – gives it rights to United’s UBT251 candidate in all global markets except mainland China, Hong Kong, Macau, and Taiwan. The drug candidate is a triple agonist – targeting GLP-1, GIP, and glucagon – and is currently in early-stage clinical development for obesity, type 2 diabetes, and other indications.
Novo Nordisk is already making massive revenues from GLP-1 agonist weight-loss drug Wegovy (semaglutide), but is facing strong competition...
Today's Sponsors
Today's Sponsor